
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia is a promising company with a strong focus on developing and commercializing innovative and novel medications to address unmet patient needs in the field of pulmonary hypertension (PH) and PH associated with interstitial lung disease. The company's proprietary PRINT technology, a particle engineering platform, allows for precise and uniform production of drug particles, giving them an advantage in the market. Furthermore, their lead product Yutrepia has shown strong performance in the market and is expected to reach blockbuster status. With a large, underpenetrated market and a differentiated technology, we believe Liquidia is well positioned for growth and have a positive outlook on the company's stock.
Bears say
Liquidia is currently facing legal challenges surrounding their product Yutrepia, with the recent Supreme Court ruling validating the possibility of a narrow label-based outcome, although the situation remains different from the Amarin v. Hikma case due to Yutrepia already being approved and marketed for the same indications as competing products. Despite this, Liquidia has reported strong sales and prescription growth for Yutrepia, but there is uncertainty surrounding the company's exclusivity and potential competition in the future. As a result, the current risk environment for Liquidia remains high, with legal decisions potentially impacting the company's financial performance.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares